Literature DB >> 16733826

[Technical limits of PET/CT with 18FDG in prostate cancer].

D von Mallek1, B Backhaus, S C Müller, A Matthies, H Palmedo, U Jaeger, H-J Biersack, M Reinhardt.   

Abstract

There is increasing evidence that (18)FDG-PET is not useful for the imaging of primary prostate cancer. The aim of this examination was to prove whether or not these poor results are due to technical deficiencies of the examination method like older image reconstruction techniques, extensive (18)FDG-tracer activity in the bladder or improper contrast staining of the rectum. We examined three patients with primary prostate cancer using a modern combined PET/CT system, continuous irrigation of the bladder and an air-inflated rectal balloon catheter. PET/CT images show an exact depiction of both the prostate and all surrounding anatomic structures but no enhanced uptake of radiotracer in the tumour. Therefore, the mentioned poor results of (18)FDG-PET seem not to be due to technical deficiencies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733826     DOI: 10.1055/s-2006-932129

Source DB:  PubMed          Journal:  Aktuelle Urol        ISSN: 0001-7868            Impact factor:   0.658


  5 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

2.  Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.

Authors:  E J Han; J H O; W H Choi; I R Yoo; S K Chung
Journal:  Br J Radiol       Date:  2010-11       Impact factor: 3.039

Review 3.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

4.  Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography.

Authors:  Manoj Gupta; Partha Sarathi Choudhury; Sudhir Rawal; Harish Chandra Goel; Shriram Avinash Rao
Journal:  Urol Ann       Date:  2019 Apr-Jun

Review 5.  Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.

Authors:  Sandra Bednarova; Maria L Lindenberg; Maria Vinsensia; Chiara Zuiani; Peter L Choyke; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2017-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.